Cliff Asness's HAE Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 2.1M shares of Haemonetics Corporation (HAE) worth $102.81 M, representing 0.07% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 52 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in HAE, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2025, adding 1.7M shares. Largest reduction occurred in Q2 2019, reducing 411.9K shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Haemonetics Corporation (HAE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Haemonetics Corporation (HAE) Trades by Cliff Asness
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2012 | +6,202 | Add 0.00% | 6,200 | $40.81 |
| Q2 2013 | +6,201 | Add 0.00% | 6,200 | $41.29 |
| Q3 2013 | -6,200 | Sold Out | 6,200 | $0.00 |
| Q2 2015 | +14,619 | New Buy | 14,619 | $41.38 |
| Q3 2015 | -6,222 | Reduce 42.56% | 8,397 | $32.27 |
| Q4 2015 | -8,397 | Sold Out | 8,397 | $0.00 |
| Q2 2016 | +43,359 | New Buy | 43,359 | $28.99 |
| Q3 2016 | +2,530 | Add 5.84% | 45,889 | $36.20 |
| Q4 2016 | -37,687 | Reduce 82.13% | 8,202 | $40.23 |
| Q2 2017 | -8,202 | Sold Out | 8,202 | $0.00 |
| Q3 2017 | +4,764 | New Buy | 4,764 | $44.92 |
| Q4 2017 | +6,592 | Add 138.37% | 11,356 | $58.12 |
| Q1 2018 | +84,057 | Add 740.20% | 95,413 | $73.17 |
| Q2 2018 | +82,213 | Add 86.17% | 177,626 | $89.68 |
| Q3 2018 | +270,157 | Add 152.09% | 447,783 | $114.58 |
| Q4 2018 | +420,673 | Add 93.95% | 868,456 | $100.05 |
| Q1 2019 | +215,054 | Add 24.76% | 1.08 M | $87.48 |
| Q2 2019 | -411,879 | Reduce 38.01% | 671,631 | $119.35 |
| Q3 2019 | -372,530 | Reduce 55.47% | 299,101 | $126.14 |
| Q4 2019 | -147,400 | Reduce 49.28% | 151,701 | $114.90 |
| Q1 2020 | -108,264 | Reduce 71.37% | 43,437 | $99.66 |
| Q2 2020 | +14,964 | Add 34.45% | 58,401 | $87.58 |
| Q3 2020 | +22,640 | Add 38.77% | 81,041 | $86.10 |
| Q4 2020 | -23,527 | Reduce 29.03% | 57,514 | $118.56 |
| Q1 2021 | -22,706 | Reduce 39.48% | 34,808 | $111.01 |
| Q2 2021 | +56,287 | Add 161.71% | 91,095 | $66.07 |
| Q3 2021 | -21,870 | Reduce 24.01% | 69,225 | $70.60 |
| Q4 2021 | -62,216 | Reduce 89.88% | 7,009 | $53.07 |
| Q1 2022 | +18,704 | Add 266.86% | 25,713 | $62.46 |
| Q2 2022 | -18,279 | Reduce 71.09% | 7,434 | $64.70 |
| Q3 2022 | +34,849 | Add 468.78% | 42,283 | $74.03 |
| Q4 2022 | +16,916 | Add 40.01% | 59,199 | $78.35 |
| Q1 2023 | +90,092 | Add 152.19% | 149,291 | $82.17 |
| Q2 2023 | +57,790 | Add 38.71% | 207,081 | $85.14 |
| Q3 2023 | -10,584 | Reduce 5.11% | 196,497 | $89.58 |
| Q4 2023 | -57,579 | Reduce 29.30% | 138,918 | $85.51 |
| Q1 2024 | -10,143 | Reduce 7.30% | 128,775 | $84.38 |
| Q2 2024 | -44,787 | Reduce 34.78% | 83,988 | $82.73 |
| Q3 2024 | -69,988 | Reduce 83.33% | 14,000 | $80.38 |
| Q4 2024 | +11,240 | Add 80.29% | 25,240 | $77.27 |
| Q1 2025 | +149,325 | Add 591.62% | 174,565 | $62.62 |
| Q2 2025 | +275,683 | Add 157.93% | 450,248 | $74.16 |
| Q3 2025 | +1.68 M | Add 372.82% | 2.13 M | $48.29 |
Cliff Asness's Haemonetics Corporation Investment FAQs
Cliff Asness first purchased Haemonetics Corporation (HAE) in Q4 2012, acquiring 6,200 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Haemonetics Corporation (HAE) for 52 quarters since Q4 2012. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's largest addition to Haemonetics Corporation (HAE) was in Q3 2025, adding 2,128,878 shares worth $102.81 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 2,128,878 shares of Haemonetics Corporation (HAE), valued at approximately $102.81 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Haemonetics Corporation (HAE) represents approximately 0.07% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's peak holding in Haemonetics Corporation (HAE) was 2,128,878 shares, as reported at the end of Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.